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Background: The Portuguese National Health Directorate has issued clinical practice guidelines on prescription of
anti-inflammatory drugs, acid suppressive therapy, and antiplatelets. However, their effectiveness in changing actual
practice is unknown.
Methods: The study will compare the effectiveness of educational outreach visits regarding the improvement of
compliance with clinical guidelines in primary care against usual dissemination strategies. A cost-benefit analysis
will also be conducted. We will carry out a parallel, open, superiority, randomized trial directed to primary care
physicians. Physicians will be recruited and allocated at a cluster-level (primary care unit) by minimization. Data will
be analyzed at the physician level. Primary care units will be eligible if they use electronic prescribing and have at
least four physicians willing to participate. Physicians in intervention units will be offered individual educational
outreach visits (one for each guideline) at their workplace during a six-month period. Physicians in the control
group will be offered a single unrelated group training session. Primary outcomes will be the proportion of
cyclooxygenase-2 inhibitors prescribed in the anti-inflammatory class, and the proportion of omeprazole in the
proton pump inhibitors class at 18 months post-intervention. Prescription data will be collected from the regional
pharmacy claims database. We estimated a sample size of 110 physicians in each group, corresponding to 19
clusters with a mean size of 6 physicians. Outcome collection and data analysis will be blinded to allocation, but
due to the nature of the intervention, physicians and detailers cannot be blinded.
Discussion: This trial will attempt to address unresolved issues in the literature, namely, long term persistence of
effect, the importance of sequential visits in an outreach program, and cost issues. If successful, this trial may be the
cornerstone for deploying large scale educational outreach programs within the Portuguese National Health
Service.
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Patients often do not receive treatment that is supported
by best evidence. This includes both failure to provide
treatment proven to be cost-effective and provision of care
that is unnecessary or harmful [1]. High quality clinical
guidelines synthesize the current best knowledge, make
transparent recommendations for current best practice,
and can improve the quality of care [2]. However, it is re-
cognized that guidelines alone are insufficient to change
clinical practice and that implementation strategies are
required [3-5].
There is a wide range of such strategies but limited evi-
dence to assess their comparative effectiveness, as there
are few head-to-head trials. Some overviews of systematic
reviews provide narrative synthesis of the evidence sup-
porting the different interventions [1,4,6,7]. However, pri-
mary studies are too diverse and heterogeneous to allow
for more robust methods of indirect comparison. The
Cochrane Collaboration Effective Practice and Organi-
zation of Care Group has assessed several strategies
through high quality systematic reviews. Printed educa-
tional materials have no apparent effect on processes of
care, while educational meetings, educational outreach,
local opinion leaders, audit and feedback, computerized
reminders, and tailored interventions are associated with
small but clinically significant improvements [8-14].
Educational outreach interventions are personal visits
by a trained individual (hereafter named as detailer) to
health professionals in their own settings [10]. This de-
tailer is usually a healthcare professional (physician, nurse
or pharmacist) with special training in communication
skills. He or she presents educational contents prepared
by an independent organization (such as a university) to
an individual physician. The Cochrane Review estimates a
small but consistent effect on prescription improvement
(median 4.8%, interquartile range 3.0% to 6.5%) [10].
Local context
In Portugal, healthcare is provided by two overlapping sys-
tems: a publicly funded National Health Service (NHS),
and voluntary private and public health insurance. The
NHS has universal coverage, and 20% of the population
has additional insurance coverage [15]. Thus, most pri-
mary care is provided by the NHS.
NHS Primary care physicians work in units typically
with 4 to 12 doctors, along with nurses and secretaries.
On average, each family physician cares for about 1,700
patients. The NHS distinguishes two types of primary care
units. The default one is the ‘personalized care units’
model, in which professionals receive a fixed salary. The
other model is the ‘family health units’, which enjoy
greater functional and organizational autonomy [16].
‘Family health units’ start as type-A units, in which profes-
sionals receive a fixed salary as in the former model. Ifthese A units meet quality indicators targets, they become
type-B units, in which health professionals have a mixed
payment scheme that includes salary, capitation, and pay
for performance.
Within this context, prescription drugs have a variable
patient co-payment, depending on their therapeutic value
[15]. Electronic prescribing has been mandatory for all
NHS reimbursed drugs since 2012. All prescription infor-
mation is collected centrally by NHS [17].
National prescribing guidelines are commissioned by
the National Health Directorate (a government agency)
to academic researchers and key opinion leaders. This
agency also monitors the quality indicators set in each of
its guidelines [18,19]. These guidelines are published in
the agency’s website (www.dgs.pt). Health professionals
are expected to visit this website regularly to keep up-to-
date with the latest guidelines. Therefore, this study will
not have a group of naive physicians unexposed to
guidelines. For this reason, the control group is com-
posed of physicians exposed to passive guideline dis-
semination (the usual implementation strategy).
Choice of design
The design is a parallel, open, cluster, superiority ran-
domized trial with a 1:1 allocation ratio. This study will
assess the effect of educational outreach visits on phy-
sician compliance with prescription guidelines. Although
the intervention is targeted at individual physicians,
there is a risk of contamination if the randomization oc-
curs at the individual level. This is because physicians in
the same practice might be influenced by intervention
subjects (e.g., by raising awareness of the topics, through
discussion of difficult patient cases, or by sharing visit
content). Therefore, a cluster-randomized design is ap-
propriate. Also, the costs (e.g., travel expenses, salary
costs of the detailers) in a cluster-randomized design will
better approach the real costs of this intervention if
implemented as a public health program. Therefore, to
minimize contamination and for practical reasons, the
unit of allocation will be the primary care unit. The unit
of analysis will be the family physician.
Aim and objectives
This trial aims to assess whether educational outreach
visits are superior to usual implementation of guidelines
regarding the reduction of inappropriate prescribing.
The primary outcomes will be the long-term (18 months)
effects in the prescription of cyclooxygenase-2 (COX-2)
inhibitors, and omeprazole, by family physicians. The
secondary outcomes will be the short (1 month) and
medium-term (6 months) effects of educational outreach
visits in the prescription of these two drug classes. Other
secondary endpoints will be the short, medium and
long-term effects of educational outreach visits in the
Pinto et al. Implementation Science 2014, 9:10 Page 3 of 9
http://www.implementationscience.com/content/9/1/10prescription of clopidogrel. Finally, the trial will deter-
mine the cost-benefit of educational outreach visits.
Methods
The study will be a parallel, cluster-randomized con-
trolled trial comparing educational outreach visits with
usual guideline implementation. Besides the standard de-
scription below, we also provide a summary of the inter-
vention, a PaT plot, and a cascade diagram in Additional
file 1 [20,21]. This protocol was written in accordance
with the Consolidated Standards of Reporting Trials
(CONSORT) statement - Additional file 2.
Participants and setting
The trial will recruit family physicians employed in
primary care units of the National Health Service of
the Lisbon region, Portugal. This region comprises over
3.5 million patients. A primary care unit (the cluster) will
be eligible if it has at least four family physicians (which
represent about 6,800 patients). Physicians that areFigure 1 Flow of participants.planning to retire within two years, and those without an
assigned or still building (far from the average number of
patients) patient list will be excluded. At least four family
physicians in each unit have to be willing to participate in
order for the unit to be included in the trial.
The expected participant flow is described in Figure 1.
The research authors will meet with the coordinators of
each unit, briefly explaining the protocol and extending
them an invitation to participate. The coordinators will
be asked to share trial information with other physicians
in their units. The researchers will then contact and
screen willing primary care units until the target number
is met. The enrollment period will last six months.
There will be no financial incentive for participation.
Baseline data will be collected from the primary care
units (number of family physicians, type of primary care
unit, urban versus rural setting, baseline prescription of
COX-2 inhibitors, baseline prescription of omeprazole)
and from the family physicians (age, gender, number
of years of practice after vocational training, currently
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schedule three educational outreach visits, one for each
guideline.
Allocation to intervention and blinding
Clusters will be enrolled and allocated randomly. To
achieve a good balance regarding baseline characteristics
that can influence the outcome, the allocation sequence
will be determined by minimization [22]. This stratified
randomization method will balance the control and inter-
vention groups for number of physicians (4 or 5, 6 or 7, 8
to 12), median baseline prescription of COX-2 inhibitors
(above or below the regional median), median baseline
prescription of omeprazole (above or below the regional
median), proportion of physicians with fewer than 10
years of practice after completing vocational training
(above or below 50%), and type of primary care unit
(family health unit or personalized care unit). All phy-
sicians sending the consent statement before the cluster
allocation will be included in the study.
The sequence of intervention visits for each unit will
be determined by simple randomization.
Allocation concealment will be ensured by the following
procedures: the trial manager (hired and not part of the
authors research team) will assign a sequential number to
each unit as participation forms are received; only ano-
nymized data about participating units will be sent to the
trial statistician (sequential number and minimization var-
iables); data will be sent in two batches, one for each half
of all units; the sequence of visits will be determined using
the random sequence generator from Random.org (http://
www.random.org/sequences/); the statistician will blindly
allocate units to each trial arm using minimization and re-
turn allocation information to the trial manager.
Due to the nature of the intervention, neither family
physicians nor detailers can be blinded. Outcomes are rou-
tinely collected by the regional health administration inde-
pendently of the researchers or the trial and will only be
sent to researchers after the intervention has ended. Upon
receiving prescription data, the trial manager will generate
a random code (using http://www.randomcodegenerator.
com) to designate intervention and control units and
another code for the order of the visits. Data analysts (the
trial statistician plus one of the members of the research
team) will receive a file with these codes, ensuring they will
be blinded to group and visit sequence allocation until all
analyses are completed.
Intervention and comparison
Physicians in units randomized to the intervention will
have three educational outreach visits during a six-month
period. These visits will promote the implementation
of governmental guidelines on the prescription of the
following agents: non-steroidal anti-inflammatory drugs(NSAIDs) and COX-2 inhibitors, acid secretion modifiers,
and antiplatelets [23-25]. The outcomes for the trial were
chosen according to the main key-message from each
guideline. For NSAIDs, COX-2 inhibitors should be pre-
scribed only in patients with increased gastrointestinal risk
who do not tolerate a classic NSAID associated with a
gastroprotective agent; for acid secretion modifiers, all
proton pump inhibitors are equivalent in effectiveness, so
omeprazole should be used in most patients as it is the
least expensive; for antiplatelets, there is no benefit of
maintaining long term clopidogrel after a myocardial in-
farction, acute coronary syndrome, or percutaneous co-
ronary intervention.
During each 15- to 20-minute visit, an academic detailer
will promote one of the guidelines to a family doctor (up
to three physicians may be present in each visit if they
wish to, but one-to-one visits will be preferred and en-
couraged). The detailer will also distribute a point of care
summary highlighting the main messages. The team of
academic detailers will be as following: three members of
the steering committee (two family physicians and one
academic pharmacologist), three family physicians, and
nine family medicine residents in the fourth and final year
of their specialty training. The three members of the steer-
ing committee completed training in the methodology of
academic detailing with the National Resource Center for
Academic Detailing (Boston, MA). The other 12 detailers
were trained locally by this steering committee, with pre-
training study assignments, and 12 hours of face-to-face
training that included the principles of academic detailing,
role-playing, video-recording and feedback, discussion of
the scientific content of each guideline, and knowledge
assessment. To ensure consistency, the contents of each
visit (structure, guideline features to highlight, and writ-
ten materials) have been prepared in advance by the
steering committee and were used in the training ses-
sions. Whenever possible, a single detailer will perform
all three visits to the same physician. The definition and
methodology of educational outreach visits has been
published elsewhere [10,26].
Usual guideline implementation consists of passive dis-
semination by their publication on the National Health
Directorate’s website. Physicians in units randomized to
the control group will be offered an unrelated training
session (coding with the International Classification of
Primary Care, second edition) as a token of good will for
participating in the trial.
This trial has a pragmatic purpose. To improve adhe-
rence to the educational outreach visits, the Regional
Health Administration will allow family physicians to
use a patient visit slot (15 to 20 minutes) for each of the
three visits, but physicians may also choose to have the
visit before or after their regular hours. The first visit
will be scheduled by the trial manager contacting the
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duled directly between the detailer and the target family
physician. Also to improve adherence, participating phy-
sicians will be asked to allow us to use their personal
phone numbers and emails. We will use these to send
them a reminder of the visit two days before it is sche-
duled. Rescheduling the visit will be allowed up to the
day before it is scheduled to take place; if the physician
is unable to attend the visit but cannot warn the detailer
beforehand, no additional efforts will be made to re-
schedule that visit (i.e., the program will continue with
the next guideline). The intervention will be discon-
tinued at physician request or if the physician changes
workplace. Participating physicians will not be prohi-
bited from receiving any other interventions during the
trial.
Outcomes
Primary and secondary outcomes
There are two primary outcomes, measured at the phy-
sician’s level. One is the proportion of COX-2 inhibitors
(anatomical therapeutic classification [ATC] M01AH)
prescribed within the entire NSAID class (ATC M01A) in
defined daily doses 18 months after the intervention. The
other is the proportion of omeprazole (ATC A02BC01)
within the entire proton pump inhibitors class (ATC
A02BC) in defined daily doses 18 months after the
intervention.
There are seven secondary outcomes, also measured at
the physician’s level: the proportion of COX-2 inhibitors
within the NSAID class at one and six months; the pro-
portion of omeprazole within the proton pump inhibi-
tors class at one and six months; and the number of
defined daily doses of clopidogrel prescribed per 1,000
registered patients at 1, 6 and 18 months. The propor-
tion of clopidogrel (ATC B01AC04) within the platelet
aggregation inhibitors (ATC B01AC) was not selected as
an outcome because the most commonly used drug in
that class is acetylsalicylic acid (ATC B01AC06). This
drug is generally sold over the counter, and no reliable
data of its consumption exists.
Timing of outcome collection
Unlike a randomized controlled trial for a drug, we do
not expect the intervention to be delivered immediately
after allocation. This is because there are a limited num-
ber of detailers, and their time for visits is also limited
(as they themselves are practicing physicians). Plus,
family physicians’ availability to receive visits from these
detailers is also constrained by their heavy workload.
These constraints will prevent us from delivering the
intervention to all physicians in a short period (e.g., less
than one month). We plan to deliver the full interven-
tion to all physicians in the experimental group over aperiod of six months. For each guideline, we will seek to
visit all the physicians belonging to the same cluster in
the shortest time possible, to limit contamination within
clusters. This will cause the gap between allocation and
intervention dates to vary depending on the participating
unit. Thus, if we assess the outcome at a fixed time
following randomization, participating units will have
different follow-up times after the intervention, and as a
result the observed intervention effect will be unreliable.
Moreover, since we will have three visits for each phy-
sician, there will also be differences in the time of inter-
vention between guidelines. For these reasons, outcomes
will be measured from specific intervention dates rather
than from the general allocation date. This will provide
more reliable data about the efficacy of the intervention.
Using the intervention dates poses a problem for the
control group, for whom these do not exist. If we were
to measure outcomes from the allocation date, there
would be up to a six-month time gap compared with
intervention units. In this relatively long interval, other
factors influencing prescription of the study drugs could
arise (e.g., new research or guidelines being published,
changes in drug policy in the Portuguese NHS, seasonal
trends of prescription of NSAIDs, etc.). We will address
this problem by randomizing the dates from which we
measure outcomes for each guideline among control
units. This will distribute control units along the inter-
vention period, making them more comparable to the
experimental group. This will be done by selecting a ran-
dom month falling within the first and last months of
the visits in the intervention group. The trial statistician
will blindly assign a random month for each guideline in
every control unit after the final visit in the intervention
group is made and before outcomes are collected.
Outcomes will be measured using the same monthly
prescription data for all physicians within a given cluster.
Cost analysis
Global prescription spending will be defined as the sum
of the cost of all drug prescriptions of NSAIDs (ATC
M01A), acid suppressive therapy (proton pump inhibitors
ATC A02BC and their alternatives: H2-receptor antago-
nists ATC A02BA, antacids ATC A02A, misoprostol ATC
A02BB01, and sucralfate ATC A02BX02), and antiplatelets
(ATC B01AC), up to 18 months after the intervention.
These costs will be compared with the amount spent
training the detailers, preparing and printing educational
materials, travel expenses to intervention units, payment
of detailers, program coordination, and physician time
spent with a detailer rather than with a patient. Costs will
be analyzed from the point of view of an educational out-
reach program rather than from conducting research.
Therefore, research related costs (such as researcher time
for data collection and analysis) will not be considered.
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control units will not be accounted for because it is only
intended to improve recruitment and would not be neces-
sary for the implementation of an educational outreach
program.
Data collection
Researchers will have access to prescription data through
a data monitoring system operated by the Regional Health
Administration. Data will be collected and provided
by employees from this Administration according to re-
searcher defined specifications. Importantly, researchers
will not be directly involved in data collection. This infor-
mation arrives with a two-month delay from the date the
prescription is dispensed. The prescription information
contained there can be either for acute conditions - single
prescriptions with up to two packages to be dispensed
within 30 days; or for chronic usage - three identical pre-
scriptions (up to two packages each) to be dispensed
within 6 months. Within the drug classes of this study,
only NSAIDs cannot be prescribed for chronic usage.
Adverse events cannot be collected in this study because
only prescription data is available.
Detailers will record whether the planned visit was
effectively accomplished, whether it had the planned
duration, the number of physicians (including residents)
present, whether the visit was made on patient visit time
or off hours, the number of times the detailer had pre-
viously visited that physician, and feedback from the
physician about the educational materials.
Sample size
The research team has obtained pilot data from all phy-
sicians of three primary care units. This data was used to
estimate within unit variability and the intra-cluster cor-
relation coefficient (ICC). Data was also gathered for all
the units in the Regional Health Administration to esti-
mate the mean prescription and standard deviation for the
primary outcomes. The mean proportion of omeprazole
dispensed was 54.0% of all PPIs (standard deviation, SD,
10.1%) and the ICC was 0.027. The mean proportion of
COX-2 inhibitors dispensed was 20.6% of all oral NSAIDs
(SD 7.4%), and the ICC was 0.249. The Cochrane review
on educational outreach visits found a median adjusted
risk difference for improvement in compliance with de-
sired practice of 5.6% (interquartile range 3.0% to 9.0%)
and 4.8% specifically for prescribing (interquartile range
3.0% to 6.5%) in previous trials [10]. Therefore, we chose
to calculate our sample size assuming the intervention
would lead to a 5% absolute difference in compliance with
guidelines between intervention and control units.
If we assume a mean cluster size of six physicians per
unit, a 1:1 allocation ratio of controls per intervention
unit, an alpha type error of 0.025, and a dropout rate ofabout 15%, then a sample of 110 physicians in each
group will allow for 80% power to demonstrate a 5%
absolute increase in the proportion omeprazole and a
5% absolute decrease in COX-2 inhibitors. To recruit
the necessary number of physicians, 38 primary care
units will be required. STATA 12.0 (STATA Corp, TX,
USA) and its sampsi and sampclus commands were used
to calculate sample size.
Statistical methods
Physicians will be analyzed according to their randomly
allocated group regardless of adherence to the interven-
tion (intention to treat analysis). If physicians transfer to
another unit within the health region, we will still be able
to monitor their prescriptions. If the transfer is to a dif-
ferent health region (i.e., not Lisbon) we will contact the
physician and ask for the missing prescription data. In
both cases, prescription of clopidogrel will be adjusted to
the new patient list. If a physician retires or we are unable
to retrieve data from a physician who moved to a dif-
ferent region, then we will use the last working month’s
prescription.
Both groups will be compared on primary outcomes
using generalized mixed-effects models. The ratio of
COX-2 inhibitors to the entire NSAID class and the ratio
of omeprazole to the entire proton pump inhibitor class
and respective 95% confidence intervals will be calculated.
Statistical significance will be assumed for a p-value less
than 0.025. STATA 12.0 (STATA Corp, TX, USA) will be
used to conduct the analysis.
Data monitoring
Given the nature of the intervention, which poses mi-
nimal risks to patients, no data monitoring committee
will be established.
Ethical approval
This protocol has been approved by the ethics commit-
tee of the Regional Health Administration of Lisbon and
Tagus Valley. Family physicians invited to participate will
receive written information about the main aspects of
the trial, namely which data are being collected and the
procedures to ensure the non-identifiability of individual
prescriber data. They will sign a written consent for re-
searchers to access their data. The trial will only collect
aggregated and non-identifiable patient data. As such,
the ethics committee waived patient informed consent.
Trial status
At the time of protocol submission, we have obtained
ethical approval and have started to contact eligible
primary care units. No primary care unit has been
randomized.
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Our pilot data about prescription of NSAIDs, acid-sup-
pressive therapy, and antiplatelet therapy suggests that
there is room for improving physicians’ prescribing, alig-
ning it with evidence, and potentially leading both to im-
provements in patient outcomes and cost savings to the
Portuguese National Health Service. This paper describes
a protocol for a cluster-randomized trial to assess whether
educational outreach visits have a long-term (18 months)
effect on physician prescriptions. Randomized trials are
the gold standard to assess intervention effects, and
cluster-randomized trials are an appropriate design when
the intervention is an education intervention targeted at
healthcare providers [27].
In this trial, it will be impossible to blind physicians
and detailers to the intervention. Lack of blinding is ex-
pected to overestimate the intervention effects [28,29].
To minimize the effect of this bias, we are using
prescription, which is an objective outcome measured
independently from the researchers. This outcome also
minimizes attrition, since it is possible to continue to
assess the prescription behavior even if a physician
changes workplace (within the same region).
We have chosen prescription-related outcomes over
clinical outcomes. In Portugal, hospital discharge diag-
noses (coded through the 9th revision of the International
Classification of Diseases) are routinely collected for hos-
pital reimbursement purposes, but are only available after
considerable delay. Primary care diagnoses (coded through
the 2nd edition of the International Classification of Pri-
mary Care) began to be collected in 2007 and are available
in the regional database within only one month of regis-
tration in the medical record. However, both hospital and
primary care diagnoses have not been validated for com-
prehensiveness and accuracy. Moreover, diagnoses asso-
ciated with incentives may be recorded more often than
those without incentives [30,31]. Hence, we have chosen
to use prescription patterns as main outcomes. All pre-
scription data in the National Health Service is gathered
by the Ministry of Health for pharmacy reimbursement
purposes. Data are available for both ordered and dis-
pensed prescriptions. Pilot data from three primary care
units showed that only about 60% of the prescribed drugs
are actually dispensed. This likely arises from several fac-
tors: lack of patient adherence to prescriptions, the inabi-
lity of physicians to match monthly amounts of different
medicines in the same prescription sheet (hence the
patient will not fill the entire prescription), and errors in
printing and composing prescriptions that are subsequentlynot handed to the patient nor removed from the elec-
tronic medical record. For all these reasons, we opted to
use dispensed prescriptions data as primary outcomes ra-
ther than ordered prescriptions.
Proton pump inhibitors and antiplatelets may be placed
in chronic prescriptions, valid for up to six months. This
means that data for these drugs may include prescriptions
as old as six months prior to dispensing (and hence up to
six months prior to the intervention). This may result in
an underestimation of the intervention’s effect in secon-
dary outcomes (one and six months, which may still
include many lingering old prescriptions). This under-
estimation will be resolved for the primary outcomes
(18 months) because by that time all prescriptions issued
prior to the intervention will have been dispensed. How-
ever, if the intervention effect decreases over time, prescrip-
tions issued as early as 12 months after the intervention
may still be dispensed at 18 months and thus lead to an
overestimation of the primary outcomes.
The intervention’s effect on physicians may change
over time. As the program moves forward, detailers are
expected to build a relationship with visited physicians.
This may improve the detailer’s ability to change the
physician’s prescribing behavior. On the other hand, the
physician’s curiosity and willingness to participate may
decrease, making him or her less receptive to the inter-
vention. To avoid confounding resulting from the order
by which each guideline is presented, we will randomly
assign the guideline order for each unit.
We are recruiting family physicians from the three types
of primary care units described in the introduction.
Preliminary data at the regional level suggests that pre-
scription patterns have greater room for improvement in
‘personalized care units’ (COX-2 inhibitors market share
within NSAIDs is 22.8% in personalized care units vs.
17.8% in family health units; and omeprazole market share
within PPIs is 53.1% in personalized care units vs. 55.5%
in family health units). However, it is possible that recruit-
ment is stronger in type A and type B ‘family care units’,
since their contracts with the Regional Health Administra-
tions state incentives for participation in research projects
and lower drug expenditure. This differential participation
may compromise the generalizability of our findings to
the Portuguese NHS, especially if physicians respond dif-
ferently to educational outreach according to the type of
unit in which they practice.
Relationship to other studies and expected contribution
of this trial
In 2008, a Cochrane Systematic review concluded that
educational outreach visits had a small but consistent ef-
fect on improving prescribing behavior, and identified
areas for further research, namely: head-to-head compari-
sons between different educational outreach strategies,
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components influence the effectiveness of the interven-
tion, inclusion of patient outcomes, measurement of costs
and sustained/long term/multiple visits educational efforts
[10]. Since its publication, a large number of trials of
multifaceted interventions that included educational out-
reach visits have been published. However, it is not yet
clear whether educational outreach has a sustained effect
and whether the intervention is cost-effective in a broad
range of healthcare systems. The current study is inno-
vative and important internationally as it addresses both
these questions. Locally, this trial may show the effective-
ness and feasibility of a sustained educational outreach
program. If successful, it may be the cornerstone for
deploying large-scale programs within the Portuguese
NHS. This may range from other types of prescription im-
provement (e.g., much needed increase of generic market
share, which in Portugal is only about half the share of
Germany or the US; targeting innovative therapy for ap-
propriate patients) to rational ordering of tests and even
adequate screening practices. Ideally, governments and
academic centers should be well positioned to apply our
findings to a variety of educational outreach programs.
Data sharing
All data is property of the Lisbon Regional Health Adminis-
tration (Portuguese Ministry of Health). Other researchers
wanting to access raw data will need to obtain authorization
from this institution before data can be shared.Additional files
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